title: Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies.
abstract: The role of high-dose therapy and autologous stem cell transplantation in diffuse large B cell lymphoma (DLBCL) after transformation is controversial. We have retrospectively analyzed patients with chemosensitive disease and a history of follicular lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma who underwent high-dose chemoradiotherapy and bone marrow transplantation (BMT) with anti-B cell monoclonal antibody-purged autologous marrow for DLBCL. Between December 1982 and August 1997, 27 patients underwent autologous BMT using a uniform ablative regimen with cyclophosphamide, total-body irradiation, and bone marrow purging. All patients received multiple chemotherapy regimens before autologous BMT. At bone marrow (BM) harvest, only 44% of patients were in complete remission, and overt BM infiltration was present in 37%. After cyclophosphamide and total-body irradiation, no treatment-related deaths were seen. Eleven of the 27 patients relapsed, and four patients developed myelodysplasia/acute myelogenous leukemia. In seven patients in whom pathologic studies were available after relapse, the histology remained DLBCL. Twelve patients remained alive and in complete remission with a median follow-up of 36 months (range 10-132). The disease-free survival and overall survival are estimated to be 46% (90% confidence interval 28-64) and 58% (40-76) at 5 years, respectively. Patients whose disease underwent histologic transformation within 18 months of their initial diagnosis of indolent lymphoma had significantly better overall survival. Selected patients with histologic transformation, particularly those whose transformation occurs early in the course of their disease and who remain chemosensitive, may experience prolonged survival after autoBMT.
authors.affiliation: Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA.
authors.forename: J W
authors.initials: JW
authors.lastname: Friedberg
authors.forename: D
authors.initials: D
authors.lastname: Neuberg
authors.forename: J G
authors.initials: JG
authors.lastname: Gribben
authors.forename: P
authors.initials: P
authors.lastname: Mauch
authors.forename: K C
authors.initials: KC
authors.lastname: Anderson
authors.forename: R J
authors.initials: RJ
authors.lastname: Soiffer
authors.forename: T
authors.initials: T
authors.lastname: Takvorian
authors.forename: D C
authors.initials: DC
authors.lastname: Fisher
authors.forename: R
authors.initials: R
authors.lastname: Schlossman
authors.forename: H
authors.initials: H
authors.lastname: Jallow
authors.forename: C
authors.initials: C
authors.lastname: Kuhlman
authors.forename: J
authors.initials: J
authors.lastname: Ritz
authors.forename: A S
authors.initials: AS
authors.lastname: Freedman
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D016393:Lymphoma, B-Cell / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000628:therapy; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy; D008297:Male; D008875:Middle Aged; D016133:Polymerase Chain Reaction / Q000379:methods; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors; D015996:Survival Rate; D014182:Transplantation, Autologous; D016896:Treatment Outcome